AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04108702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality heart
Description: Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity.
Study NCT04108702 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality control
Description: Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity.
Study NCT04108702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
Study NCT04108702 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
Study NCT04108702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
Study NCT02778867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 Food Elimination Diet (after 1FED failure)
Study NCT02778867 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Study NCT03532971 — intervention group
Intervention type: OTHER
Intervention: Symptom index questionnaire
Description: A survey administered to identify the symptoms of the patient
Study NCT03532971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BK polyomavirus PCR
Description: quantitative PCR testing
Study NCT03532971 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaires
Description: Standard questionnaires validated for HCT recipients
Study NCT00540969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Patients undergo cryosurgery using guidance from CT scan or ultrasound
Study NCT00540969 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiotherapy for 1 week
Study NCT03047993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03047993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutaminase Inhibitor CB-839
Description: Given PO
Study NCT02169284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01889797 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Rituximab
Description: Rituximab 375 mg/m² IV x 4 weekly doses.
Study NCT03716167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summus Laser
Description: infrared laser treatment
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03716167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Summus Laser Sham
Description: non-infrared light
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02169284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03117036 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Systemic chemotherapy with curative intent
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine PR
Description: Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
Study NCT02169284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo TURBT or cystectomy
Study NCT02169284 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo TURBT or cystectomy
Study NCT03048916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general swallowing therapy
Description: including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
Study NCT03048916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: general swallowing therapy
Description: including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
Study NCT03048916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES therapy
Description: he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
Study NCT03048916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES therapy
Description: he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
Study NCT01889797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm B: GA101
Description: GA101 1,000 mg (flat dose) IV x 4 weekly doses.
Study NCT02259348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)
Study NCT02259348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT02259348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV or subcutaneously (SQ)
Study NCT02259348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given SQ
Study NCT02259348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT02725892 — intervention group
Intervention type: OTHER
Intervention: NIS observational stud
Description: NIS observational study : Epidemiologic registry
Study NCT02259348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT02259348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02259348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cell therapy
Description: Given IV
Study NCT02259348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell depleted HPC transplant
Description: T-cell depleted hematopoietic stem cells will be infused on day 0.
Study NCT02259348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted HPC transplant
Description: CD45RA depleted stem cells will be infused on day 1.
Study NCT05344287 — intervention group
Intervention type: OTHER
Intervention: Typical American Diet
Description: Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
Study NCT05344287 — intervention group
Intervention type: OTHER
Intervention: Plant-Based Diet
Description: Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
Study NCT00892749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT00057967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
Study NCT03157869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
Study NCT03157869 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulated
Description: Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
Study NCT02174276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily
Study NCT02174276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily
Study NCT02174276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 2 mg
Description: Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 4 mg
Description: Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
Study NCT03655119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent toolkit
Description: The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
Study NCT03655119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
Study NCT03655119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Follow-Up Messages
Description: Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
Study NCT02102919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
Study NCT02102919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Games (VG)
Description: Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
Study NCT02102919 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
Study NCT02102919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aktiv Tramp (Swiss Frei AG, Switzerland)
Description: Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT02101073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, intravenous
Study NCT02101073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: single dose, subcutaneous
Study NCT02418624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, olaparib
Description: 2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
Study NCT01006967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveStep Treadmill
Description: The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
Study NCT03435107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Study treatment consists of durvalumab 1500 mg Q4W for patients > 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study.
Study NCT04482803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
Description: Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
Study NCT03492294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional magnetic resonance imaging
Description: Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
Study NCT03087149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monitored vit D supplementation
Description: The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
Study NCT03087149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard vit D supplementation
Description: The vitamin D supplementation dose is 500IU from 7th day of age.
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males control group: Deferred letter
Description: This letter will be sent 6 months after index (mailing) date
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 1: Current CCC invitation letter
Description: This letter is currently used by the program in 50-54 year olds
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 2: New letter with neutral gender content
Description: Unisex letter
Study NCT03908138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDD
Description: Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Males Group 3: New letter with male-specific content
Description: New letter tailored for men
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females control group: Deferred letter
Description: This letter will be sent 6 months after index (mailing) date
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females Group 1: Current CCC invitation letter
Description: This letter is currently used by the program in 50-54 year olds
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT03908138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VDD
Description: Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
Study NCT01598727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam(TM) Imaging System (Fluoptics)
Description: Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02364895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Females Group 2: New letter with neutral gender content
Description: Unisex letter
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT01008150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00251355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
Study NCT01736202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fat orally
Description: Oral ingestion of palm oil or canola oil or water at timepoint zero
Study NCT00251355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU via continuous IV infusion.
Study NCT01736202 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: fat orally
Description: Oral ingestion of palm oil or canola oil or water at timepoint zero
Study NCT00251355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiotherapy (weeks 1-6), Monday through Friday.
Study NCT02415257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 1
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 2
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 3
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 4
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 5
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: BI 691751 Dose 6
Study NCT02148107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03751644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles